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Combined ETA/ETB receptor blockade of human peritoneal
mesothelial cells inhibits collagen I RNA synthesis.
Background. Peritoneal fibrosis is a serious complication of
peritoneal dialysis; however, the mechanisms are poorly under-
stood. We studied osmolarity and physical stress-induced effects
on collagen I RNA synthesis in human peritoneal mesothe-
lial cells (HPMCs) and focused on endothelin as a possible
mediator.
Methods. HPMCs were grown in a medium containing either
D-glucose or glycerol to analyze the impact of osmolarity on
mesothelial endothelin-1 (ET-1) release and on collagen I RNA
synthesis [reverse transcription-polymerase chain reaction (RT-
PCR)]. A cellular model of nonlaminar fluid shear stress and
cellular stretch was used to analyze the effects of physical forces.
To neutralize the endothelin effects, a combined ETA/ETB re-
ceptor antagonist (LU 302 872) was choosen.
Results. Glucose, but not glycerol, increased mesothelial
ET-1 release in a concentration and time-dependent manner
(P < 0.05 vs. controls). Collagen I RNA synthesis was signifi-
cantly higher in glucose-challenged cell cultures (P < 0.05 vs.
controls). The glucose-mediated collagen I RNA synthesis was
completely inhibited by adding the combined ETA/ETB recep-
tor antagonist to the medium. Fluid shear stress, but not cellular
stretch, led to a significant increase in the mesothelial ET-1 re-
lease (P < 0.005 vs. controls) and collagen I RNA synthesis
(P < 0.05 vs. controls). LU 302 872 completely inhibited these
effects.
Conclusion. We found that glucose and fluid shear stress are
potent stimuli for ET-1 release and collagen I RNA synthesis in
a model cellular system. Although our system is highly artificial,
our findings raise the hypothesis that similar effects may occur
in the peritoneal membranes of peritoneal dialysis patients and
suggest that endothelin might be involved.
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In long-term peritoneal dialysis, chronic scarring of the
peritoneal membrane may result in treatment failure [1].
The mechanisms involved in the initiation and progres-
sion of peritoneal fibrosis are not well understood. The
dialysate is not a physiologic fluid and may play an im-
portant role. The high glucose concentrations may alter
mesothelial cell function [2–4] and trigger the release of
profibrotic mediators [5–7]. Alternatively, the high osmo-
larity could play a role [8, 9]. Multiple exchanges must be
performed throughout the day with stretching and dis-
tension of the mesothelial cells. Conceivably, mechanical
forces could be involved. Such forces are important in
regulating cell proliferation and differentiation in various
cells including endothelial cells [10, 11], vascular smooth
muscle cells [12], cardiac myocytes [13], and pulmonary
mesothelial cells [14]. We recently reported on the effects
of dwell volume and osmolarity of peritoneal dialysate
on peritoneal endothelin-1 (ET-1) release in stable peri-
toneal dialysis patients [15]. We found that increasing
dwell volumes from 1500 mL to 2500 mL per dwell led
to a significant increase in peritoneal ET-1 release. Fur-
thermore, changing the dialysate glucose concentration
from 1.36% to 3.86% activated the peritoneal ET-system.
Since endothelin is known to exert substantial profi-
brotic properties [16, 17], we reasoned that volume and
osmolarity-induced ET-1 release might play a role in the
process of fibrotic remodeling. To test this notion further,
we have conducted a series of experiments in cultured
HPMCs.
METHODS
HPMC isolation
We obtained intraoperative specimens of omentum
from patients who had given written informed consent
(IRB Charite´). The pieces (3 to 5 cm2) were washed three
times with sterile phosphate-buffered saline (PBS), pH
7.3 (PAA Laboratories GmbH, Linz, Austria), and then
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incubated with rotation in 0.25% (wt/vol) trypsin-0.01%
(wt/vol) ethylenediaminetetraacetate (EDTA) solution
(Sigma Chemical Co., St. Louis, MO, USA) for 20 minutes
at 37◦C. The tissue was then removed and trypsin solution
containing free mesothelial cells was centrifuged at 411 ×
g for 10 minutes at 4◦C. The supernatant was discarded.
The cell pellet was washed once with PBS and then
suspended in minimum essential medium D-valin (Life
Technologies, Grand Island, NY, USA) supplemented
with 10% fetal calf serum (FCS) (vol/vol) (Biochrom
KG, Berlin, Germany), 100 U/mL penicillin (Biochrom
KG), 100 lg/mL streptomycin (Biochrom KG), and
2 mmol/L L-glutamine (Biochrom KG). After seeding
into uncoated 75 cm2 tissue culture flasks, the cells were
maintained in the same medium and incubated at 37◦C
under an atmosphere of 5% CO2/95% air in a humidified
incubator. The medium was replaced every 2 to 3 days.
HPMCs from the second passage were used for the ex-
periments. Confluent cells were polygonal and formed
a regular monolayer in light microscopy. HPMCs were
characterized by the alkaline phosphatase-antialkaline
phosphatase (APAAP) technique. For experiments with
endothelin antagonist, we used a combined ETA/ETB
receptor antagonist (LU 302 872) in a concentration of
10−7 mol/L. The manufacturer kindly supplied the com-
pound. The ETA/ETB receptor antagonist LU 302 872
was added to the medium at the same time as admin-
istration of the various stresses were started. Conflu-
ent HPMCs were incubated in serum-free medium for
24 hours before starting the experiments. Cell viability
was assessed by trypan blue. At the end of the experi-
ments viability was more than 90%.
Analyzing osmolar effects
The cells were incubated in a serum-free medium
supplemented or not with D-glucose or glycerol. The os-
molytes were added to the medium to increase the osmo-
larity from 290 mOsm/kg (normal osmolarity) to either
300 mOsm/kg (low osmolarity condition) or 500 mOsm/
kg (high osmolarity condition). Osmolarities were mea-
sured by the freezing point depression method with a
micro-osmometer. For the measuring of the ET-1 con-
centration in the supernatant, conditioned media were
collected every 24 hours for 96 hours.
Analyzing physical forces
Reports on fluid-induced shear stress are generally
based on laminar flow models. However, in peritoneal
dialysis fluid, fluctuation within the abdomen generates
nonlaminar fluid shear stress. We attempted to mimic
these effects. HPMCs were placed onto a rotating shaker
(KS 125 Basic) (IKA Labortechnik, Staufen, Germany)
and fluid shear stress was induced by a constant rotation
of the plates (100 rpm). To analyze the effect of cellular
stretch, we used a method similar to that described by
Wirtz and Dobbs [18]. HPMCs (5 × 104 cells/25 mm di-
ameter well) were seeded into silicone elastomer 6-wells
plates (Flex I plates) (Flexercell, McKeesport, PA, USA)
and cultured in 2 mL/well medium. The membranes were
stretched by applying cyclic air pressure from below. Air
pressure was pump-driven and valve-controlled. The fre-
quency of oscillations was set at 50 cycles/min. A 20%
increase in the membrane surface area was targeted. The
surface area of the elastic membrane was determined by
measuring the height of membrane displacement and cal-
culating the increase in surface area from the formula for
the area of a sphere. According to Wirtz and Dobbs [18],
a 20% increase in the surface area of a silicone membrane
translates in an effective increase of cellular surface area
of approximately 15%.
Mesothelial cells were exposed to fluid shear stress or
cellular stretch for 72 hours.
Reverse transcription-polymerase chain
reaction (RT-PCR)
Total RNA from cultured HPMCs was extracted with
Trizol (Life Technologies) and reverse transcribed into
single-stranded wild-type cDNA (GeneAmp RNA PCR
Core Kit) (Perkin-Elmer, Branchburg, NJ, USA) accord-
ing to the manufacturer’s instruction.
The single-stranded wild-type cDNA was subjected to
a PCR with modified primer pairs in order to create
internal cDNA competitive reference standards (CRS).
All DNA sequences used for the design of the PCR
primers were obtained from www.ncbi.nlm.nih.gov. The
downstream primers were complementary to the mRNA
strands. Their 3′ ends were linked to an additional
sequence, complementary to a region 50 to 70 bp up-
stream on the mRNA in relation to their 5′ starting se-
quence. This resulted in a 50 to 70 bp deletion in the final
PCR-product. The upstream primers were identical in
sequence to the mRNA strands except that their 5′ ends
were coupled with a T7-promotor sequence.
The PCR product was separated on a 2% agarose
gel and stained with ethidium bromide. In order to en-
sure identical PCR conditions for the template and for
the CRS, a single-stranded cDNA CRS was generated.
Therefore, double-stranded cDNA bands were excised
from the gel, eluted using the Quiagen Gel Extraction
Kit (Quiagen, Hilden, Germany) and transcribed into
cRNA with the Riboprobe T7 System (Promega, Madi-
son, WI, USA). The amount of extracted cRNA was de-
termined by ultraviolet spectrophotometry at 260nm, and
0.5lg cRNA were reverse transcribed into internal single-
stranded cDNA CRS. Finally, the concentration of single-
stranded cDNA was determined.
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Table 1. Primer sequences for the construction of internal cDNA control reference standards, for competitive polymerase chain reaction (PCR)
as well as for the characterization of the endothelin system [endothelin-1 (ET-1), ETA and ETB rezeptor, endothelin-converting enzyme].
Internal cDNA competitive reference standards (CRS) were constructed using modified primers. The 5′ end of the upstream-primer (sense,
sequence 1) was coupled with a T7- promoter sequence. The 3′ end of the downstream-primer (antisense, sequence 1) was linked to an additional
sequence (sequence 2), complementary to a region 50 to 70 bp upstream
First nucleotide of the Estimated PCR
Primer Nucleotide-Sequence primer sequence bp product size bp
Collagen I
Sense T7 promoter 5′-AAT TTA ATA CGA CTC ACT ATA GGG A-3′
Sequence 1 5′-CG CAC ATG CCG TGA CTT GAG ACT CA-3′ 606
Antisense Sequence 1 5′-CCA CCG ATG TCC AAA GGT GCA AT-3′ 1155 572
Sequence 2 5′-A GCA GCC ATC TAC AAG AAC AGT GTA A-3′ 1052 495
GAPDH
Sense T7 promoter 5′-AAT TTA ATA CGA CTC ACT ATA GGG A-3′
Sequence 1 5′-CG TCT TCA CCA CCA TGG AGA A-3′ 375
Antisense Sequence 1 5′-CCA GTG AGC TTC CCG TTC AGC TC-3′ 742 390
Sequence2 5′-TCC GGG AAA CTG TGG CGT GAT GGC 3′ 648 321
ET-1
Sense 5′-GCA GTC TTA GGC GCT GAG CTC AGC G-3′ 267 458
Antisense 5′-AGG TGT TCC TCT GAA CTT CTT CTG ATT-3′
ETA rez
Sense 5′-GCA GAA GTC CTC GGT GGG GAT CA-3′ 976 570
Antisense 5′-CCG ATG TAA TCC ATG AGC AGT AAG-3′
ETB rez
Sense 5′-GGA CCC ATC GAG ATC AAG GAG ACT-3′ 511 504
Antisense 5′-GGG ATG AAG CAA GCA GAT TCG CAG A-3′
ECE
Sense 5′-CCC GCC ATC AAC TGG TGG CCT TT-3′ 1055 779
Antisense 5′-CAG CTC ATG GCC CAC GAC GAC AC-3′
Abbreviations are: GAPDH, glyceraldehyde-3-phosphate dehydrogenase; ET-1, endothelin-1; ECE, endothelin-converting enzyme.
All DNA sequences used for the design of the PCR primers were obtained from www.ncbi.nlm.nih.gov. All PCR products were sequenced to confirm identity.
Constant amounts of single-stranded wild-type cDNA
(0.5 lL) together with serial dilutions [1:3 for colla-
gen I, 1:5 for glyceraldehyde-3-phophate dehydroge-
nase (GAPDH)] of single-stranded cDNA CRS (starting
concentrations, 2 lg) were coamplified in a PCR mixture
for which we used non-modified primer pairs (Table 1).
PCR products were then directed to agarose gel elec-
trophoresis (2%), visualized by ethidium bromide stain-
ing, and photographed with a digital camera (Kodak DC
40, Rochester, NY, USA). Two different bands were dis-
tinguishable due to the smaller size of the cDNA CRS
as compared to target cDNA. As charged by compar-
ison with a 100 bp DNA-ladder (Rapidozym, Berlin,
Germany), PCR products proved to be consistent with
their predicted size. Sequencing of the PCR products
confirmed the identity of the amplified target genes
(Replicon, Berlin, Germany). Band intensities were den-
sitometrically analyzed through the use of the One-
Dimensional Image Analysis Software (Kodak Digital
ScienceTM). The relative amount of target mRNA was
calculated through the use of a log-log scale plot of the ra-
tio of PCR products (cDNA CRS band intensities/target
cDNA band intensities) versus the known amount of
cDNA CRS used in the competitive PCR reactions. When
target and CRS values were equivalent, the amount of
target was equal to the known amount of internal CRS.
In order to exclude nonspecific changes in total mRNA
synthesis, the value of target mRNA was normalized to
expression of GAPDH mRNA. Negative controls were
performed with target cDNA only, with cDNA CRS only
and without cDNA in order to exclude contaminating
DNA.
Characterization of the mesothelial endothelin
system by PCR
All DNA sequences used for the design of the PCR
primers were obtained from www.ncbi.nlm.nih.gov.
Table 1 provides detailed information on primer se-
quences, the first nucleotide of the primer sequence as
well as the estimated product size. All PCR products were
sequenced to confirm identity.
STATISTICS
Statistical analysis was carried out with the SPSS Sys-
tem (Release 10.0). Only nonparametric tests were used
for comparison. The Mann-Whitney U test was used for
unpaired data, the Wilcoxon signed rank test was used
for paired data. Results are expressed as mean ± SE. A
P value <0.05 was regarded as significant.
RESULTS
Characterization of cultures of HPMC
Confluent cells were polygonal and formed a regular
monolayer in light microscopy. They expressed cytoker-
atin and vimentin but failed to react with the endothelial
marker von Willebrand factor.
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Fig. 1. Electron-microscopic examination of mesothelial cells. (A) Mesothelial cells express a huge number of microvilli on the surface. Mi-
cropinocytotic vesiscles can be observed on the cell membrane. In the cytoplasma, numerous organels can be detected such as the endoplasmic
reticulum, lamellar bodies, mitochondria, and the Golgi complex. (B) Mesothelial cells are tightly bound to each other by cell interaction. In this
scan a tight junction is shown.
By electron microscopy, mesothelial cells showed api-
cal microvilli and tight junctions (Fig. 1).
Characterization of mesothelial endothelin
system by PCR
Mesothelial cells expressed genes for ET-1, the ET-A
and ET-B receptors, as well as for the endothelin-
converting enzyme.
Osmotic agents and mesothelial ET-1 release
Confluent mesothelial cell cultures exposed to glu-
cose media showed a marked increase in ET-1 release
compared to glycerol or unchallenged control medium
(Fig. 2). High glucose (500 mOsm/kg) medium led to the
highest ET-1 release and values at 72 and 96 hours dif-
fered significantly from that of glycerol (500 mOsm/kg)
challenged or osmolyte-free medium (290 mOsm/kg)
(P < 0.05). Low glucose (300 mOsm/kg) also had a ten-
dency toward increasing ET-1 values over time (0.1 >
P > 0.05). The percent increase in ET-1 release for high
glucose was greater than that for high glycerol medium
compared to osmolyte-free medium. At 72 hours, mean
values were 78% ± 18% for glucose and 5% ± 9% for
glycerol (P < 0.05).
Fluid shear stress
Fluid shear stress led to increased the mesothelial ET-1
release compared to nonstressed HPMCs. Mean ET-1 val-
ues at 72 hourw were 3.3 ± 0.4 fmol/mL for HPMCs ex-
posed to continuous fluid shear stress and 2.1 ± 0.4 fmol/
mL for nonstressed HPMCs (P < 0.005). Combining fluid
shear stress with high glucose medium (500 mOsm/kg) did
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Fig. 2. Osmolar effects on human peritoneal mesangial cells (HPMC)
endothelin-1 (ET-1) release. Glucose led to a concentration and time-
dependent increase in mesothelial ET-1 release. Values at 72 and
96 hours differed significantly (N = 10 for each experiment). ∗P < 0.05
from standard and glycerol medium.
not increase ET-1 release further. Mean values were 3.0 ±
0.4 fmol/mL. Blocking the ETA and ETB receptors dur-
ing the fluid shear stress experiments led to a significant
increase in mesothelial ET-1 release (P < 0.05) (Fig. 3).
Cell stretch
Mesothelial cell cultures grown in standard medium
and exposed to cyclic cellular stretch tended to show
higher ET-1 values compared to nonstressed HPMCs
(0.1 > P > 0.05). Mean values were 2.1 ± 0.2 fmol/mL for
cellular stretch compared to 1.8 ± 0.4 fmol/mL for non-
stressed cell cultures. Combining high glucose medium
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Fig. 3. Endothelin-1 (ET-1) release of human peritoneal mesangial
cells (HPMC) exposed to continuous fluid shear stress (72 hours).
Adding the combined ETA/ETB receptor antagonist LU 302872 to the
culture medium led to a significant increase in ET-1 release (N = 8 for
each experiment). ∗P < 0.05.
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Fig. 4. Endothelin-1 (ET-1) release of human peritoneal mesangial
cells (HPMC) exposed to high glucose medium (500 mOsm/L) with
and without cellular stretch. High glucose medium in combination with
cellular stretch led to a significantly higher ET-1 release compared to
the unstretched controls (P < 0.05).
and cellular stretch led to a significant increase in the
mesothelial ET-1 release compared to nonstressed cells
grown in high glucose medium (P < 0.05) (Fig. 4).
Collagen I RNA synthesis
HPMCs exposed to high glucose medium showed a
mean increase of 118% (20% to 320%) in collagen I RNA
synthesis compared to cells grown in standard medium
(P < 0.05) (Fig. 5A). Glycerol led to a 23% (−49% to
75%) increase in collagen I RNA synthesis compared to
unchallenged cells (NS) (Fig. 5B). Adding the combined
ETA/ETB receptor antagonist LU 302 872 to mesothe-
lial cell cultures incubated with high glucose media com-
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Fig. 5. Human peritoneal mesangial cells (HPMC) cultures. (A)
HPMC cultured in high glucose medium (500 mOsm/kg) showed a sig-
nificant increase in collagen I RNA synthesis compared to nonstressed
controls. This effect was inhibited by the ETA/ETB antagonist LU 302
872. The percent increase in HPMC collagen I RNA release differed
significantly between both groups (N = 3 to 8 for each experiment). ∗P
< 0.05. (B) Glycerol (500 mOsm/kg) had almost no effect on HPMC
collagen I RNA synthesis (N = 3 to 8 for each experiment, NS).
pletely inhibited collagen I RNA synthesis (Fig. 5A). The
combined ETA/ETB receptor antagonist had no effect
in HPMC cultures grown in high glycerol or osmolyte-
free medium (Fig. 5B). RT-PCR for collagen I RNA of
HPMCs cultured in high glucose was greater than con-
trol medium (Fig. 6). Fluid shear stress increased colla-
gen I RNA synthesis in HPMCs by 52% (19% to 110%)
compared to nonstressed cells (P < 0.05). Adding the
combined ETA/ETB receptor antagonist to cell cultures
exposed to fluid shear stress reduced (P < 0.05) collagen I
RNA synthesis to values of nonstressed HPMCs (Fig. 7).
The combination of fluid shear stress and high glucose
medium tended to achieve slightly higher values for
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Fig. 6. Reverse transcription-polymerase chain reaction (RT-PCR) for
collagen I RNA for human peritoneal mesangial cells (HPMC) cultured
in high glucose (500 mOsm/kg) and control medium (290 mOsm/kg).
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Fig. 7. Human peritoneal mesangial cells (HPMC) exposed to con-
tinuous fluid shear stress (72 hours) showed a significant increase in
collagen I RNA synthesis compared to nonstressed controls. This effect
was inhibited by the ETA/ETB receptor antagonist LU 302 872. The
percent increase in HPMC collagen I RNA release differed significantly
between both groups (N = 8 for each experiment). ∗P < 0.05.
collagen I RNA synthesis (0.1 > P > 0.05). The effects of
glycerol in combination with fluid shear stress were simi-
lar to those obtained with osmolyte free medium. Cellular
stretch, either alone or in combination with glucose, had
no significant impact on collagen I RNA synthesis.
DISCUSSION
We found that glucose increases HPMC ET-1 release in
a time-dependent manner. These effects were observed at
osmolarlities in the range of those of commercial dialysis
fluids. The effects seemed to be glucose specific since high
glycerol had no impact on ET-1. High glucose, but not
glycerol, also increased HPMC collagen I RNA synthe-
sis. The combined ETA/ETB receptor antagonist inhib-
ited the increase. Fluid shear stress also increased HPMC
ET-1 release and collagen I RNA synthesis. The
ETA/ETB receptor antagonist inhibited the effect.
In good agreement with other studies [19–21], we could
also demonstrate that high glucose concentrations induce
synthesis of transforming growth factor-b (TGF-b) in
HPMCs (data not shown). TGF-b is a well-known stimuli
of endothelin [22]. Thus, the observed activation of the
endothelin system might be, at least partially, secondary
to the enhanced TGF-b release.
ET-1 has shown to directly stimulate collagen I syn-
thesis in vascular smooth muscle cells from coronary ar-
teries and the aorta [17]. Furthermore, ET-1 stimulates
fibrogenic activity in various organs by regulating pro-
duction and turnover of matrix components [23]. ET-1
is implicated in fibrotic diseases such as systemic sclero-
sis [24, 25], pulmonary fibrosis [26], and hepatic fibrosis
[27]. Moreover, ET-1 overexpression in transgenic mice
[16] and ET-2 in transgenic rats [28] causes renal fibro-
sis. These observations would support a possible mech-
anistic role of ET-1 in peritoneal fibrosis. We recently
observed that by increasing the dwell volume or the
glucose-induced osmolarity of the peritoneal dialysis
fluid, we could activate the peritoneal paracrine endothe-
lin system [15]. Our present findings suggest glucose and
fluid shear stress are the primary triggers. In addition, we
present evidence that links the activated mesothelial en-
dothelin system to the profibrotic process within the peri-
toneum. Glucose is known as a potent stimulant for the
paracrine ET-system [16, 29, 30]. Furthermore, high glu-
cose concentrations may enhance ET-1 promoter activity
in primary mesangial cells [31]. In experimental animal
models of diabetes, blocking the ET-system has shown to
ameliorate glucose-induced end organ damage [32–34].
The above-mentioned studies are especially important
since the structural alterations of the peritoneum dur-
ing peritoneal dialysis are very similar to vascular and
tissue alteration seen in diabetes. The tissue alterations
during long-term peritoneal dialysis include a thicken-
ing and replication of basement membrane of the peri-
toneal capillaries, angiogenesis as well as a thickening
and fibrotic remodeling of the submesothelial tissue [35,
36]. Peritoneal dialysis has even been considered as
an experimental model for diabetic microangiopathy in
humans [37].
The exact mechanisms on how glucose induces fibrotic
remodeling and basement membrane thickening are still
under investigation. Evidence from in vitro studies of vas-
cular cells suggest that an increased activation of protein
kinase C (PKC) is intricately involved in this process [38,
39]. PKC activation has been associated with the acti-
vation of vasoactive factors such as vascular endothelial
growth factor and ET-1 [40]. Hence, it is conceptually pos-
sible that some of the actions of PKC in hyperglycemia
are mediated via ET-1. Chen et al [41] demonstrated
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that endothelial cells, cultured in 25 mmol/L glucose, up-
regulated the expression of extracellular matrix proteins
via ET-1 through activation of nuclear factor-kappa B
(NF-jB) and activating protein-1 (AP-1). ET-receptor
antagonism prevented extracellular matrix mRNA
expression [34].
Also, vascular permeability seem to be effected by al-
teration of the endothelin system. This is of particular
importance since vascular permeability directly impacts
on transport characteristics of the peritoneal membrane
during peritoneal dialysis [42]. Chen et al [43] inves-
tigated ET-1 expression in human umbilical vein en-
dothelial cells (HUVEC) in response to glucose and
the functional significance of these mechanisms. Per-
meability across HUVEC, grown in medium contain-
ing either low (5 mmol/l) or high (25 mmol/l) D-glucose
were investigated. L-glucose was used as a control. In-
creased transendothelial permeability was noted in cells
cultured in high glucose or when the cells grown in
low (physiologic) glucose were incubated with ET-1
but not when they were incubated with L-glucose. In-
creased permeability was associated with increased ET-1,
ETA, and ETB mRNA expression and augmented ET-1
immunoreactivity [43].
How fluid shear stress is converted into biochemical
signals in the peritoneum is uncertain. Mechanical forces
can affect the permeability of the cell membrane to vari-
ous ions, such as Ca2+ or K+ [44, 45]. Mechanical stimula-
tion can lead to cell depolarization by activating voltage
sensitive channels [46]. Moreover, mechanosensitive ion
channels have recently been identified [47] and charac-
terized. Fluid shear stress had a strong impact on ET-
1 release and collagen I RNA synthesis, while cellular
stretch only had only a modest effect. Cellular stretch
may represent a more physiologic stress for the intra-
abdominal mesothelial monolayer. Mesothelial cells are
constantly exposed to cellular stretch during bowel move-
ments or breathing which may have led to cellular stretch
adaptation.
ETA/ETB receptor blockade was effective in blocking
glucose-related and fluid shear stress–related effects in
our study. ETA receptor and combined receptor antag-
onists have been effective in ameliorating ET-1–related
effects in several animal models of fibrosis [48, 49]. In
some of these studies, the receptor blockade was shown
to involve reduced expression of growth factors, extra-
cellular matrix deposition, and decreasing matrix metal-
loproteinase activity [50, 51].
We are aware that our study has limitations. Although
glucose-related effects in peritoneal dialysis are easily ap-
preciated, we have not shown for certain that fluid shear
stress is a common phenomenon in peritoneal dialysis
patients. Animal models of peritoneal dialysis should be
the next step to address the impact of mechanical forces
on the induction of peritoneal fibrosis more specifically.
Nevertheless, we suggest the possibility that such stres-
sors may be clinically relevant. We raise the hypothesis
that high glucose combined with mechanical forces may
stimulate collagen I RNA synthesis. Adding a combined
ETA/ETB receptor antagonist that inhibited the effect.
Although this approach appeared very effective, we did
not examine other possible mediators that may none-
the-less be operative such as monocyte chemoattractant
protein-1, fibronection, or advanced glycation end prod-
ucts. We believe our findings may have clinical relevance
and application. If a locally applied ETA/ETB receptor
antagonist were able to indeed ameliorate peritoneal in-
jury in peritoneal dialysis patients, or possibly prolong
the utility of the therapy, such a treatment would be of
great value.
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